Strategic licensing: Turning IP into commercial value

​
December 9, 2025

In today’s competitive landscape, effective commercial licensing strategies are essential for unlocking the full value of intellectual property. This article explores four critical pillars: understanding intellectual property as a property right, the fundamentals of licensing intellectual property rights, structuring successful joint ventures and best practices for intellectual property rights management. Whether you’re navigating new markets or scaling established innovations, these tips provide a roadmap for protecting, leveraging and maximizing your IP assets.

1. Intellectual property as a property right

Intellectual property rights consist of a bundle of different rights, most of which in the UK have been created by statute and which are subject to international treaties where the signatory states grant broadly similar rights to those in the UK, thus enabling the UK owner of intellectual property rights to own and exploit similar rights in other countries.

The exact mechanism for achieving this depends on the rights and countries in question but with planning and strategic thinking it is possible for a rights holder based in the UK to become the owner of a range of international rights which will enable it to pursue a licensing strategy on a global or substantially global basis.

The majority of these rights are regarded by most jurisdictions as property rights and may therefore be the subject of a variety of legal transactions such as assignments, licences and charges. The intellectual property rights which may be the subject of a licensing strategy may include the following:

  • ‍Patents rights

Patent rights which protect inventions. The advantage of patent rights to a company is that they create a clearly marked area of technology into which competitors may not stray without the risk of becoming subject to an infringement action. Businesses can then develop their protected technology free from unfair competition. Patents are also useful – if not crucial -  for the purpose of raising finance and obtaining investment (since patents are a verifiable asset on which investors and lenders can rely). Further they facilitate the granting of rights to third parties who may wish to develop and exploit the rights and will pay for the right to do so (since patents will protect the business in which they will invest).‍

  • Copyrights‍

Copyrights are a valuable right which can be used to protect the economic value of many types of work including software and databases not least because it can last for a very long time (in many cases more than 70 years). It is an inexpensive right since it comes into being upon the creation of a qualifying work. Like other property rights it can be licensed, assigned and charged.‍

  • Confidential information and know how

The rights in which are based upon the right to take action for breach of contract or for a breach or duty to prevent unauthorised use or disclosure of the information in question – if it is confidential.‍

  • Trade marks

Trade marks protect the branding of the technology and are useful to develop the goodwill and reputation of the business that owns the technology; they can be useful to continue to protect the owner’s market notwithstanding the expiry of other rights such as patents.‍

  • Registered designs

Registered designs can be used to protect the design of aspects of products.‍

  • Unregistered designs

Unregistered designs can also be used to protect the design of products but typically have a shorter life than registered designs and do not need to undergo a formal registration process so are cheaper to obtain.‍

  • Database rights

Database rights are primarily a UK and EU right which protection certain databases from unauthorised extraction and re-utilisation of the data in them.

In order to be able to exploit an intellectual property right by licensing the rights to a third party it is critical for the would-be licensor either to own the rights in question or to be a licensee of such rights with the right to sub-license them. Typically the creator or author of the technology or works to which the rights relate will be the first owner – or it will be the employer of such rights. However it is increasingly common for entities to employ the services of consultants or other contractors to develop such work and if this is the case it is crucial they obtain assignments of the rights in questions in order to protect them (e.g. by filing patent applications in respect of the technology), to maintain and enforce such rights and to seek investment on the basis that they are owned by the entity seeking investment. It is very common in the headlong rush to develop technology that this is forgotten about which can have dire consequences down the line.

2. Licensing intellectual property rights

Licences are contracts whereby one party (the “Licensor”) permits the other party (the “Licensee”) to use the Licensor’s intellectual property (either owned by the Licensor – the more usual case- or licensed to it by a third party owner – a more complex scenario since the owner’s rights need to be taken into account) since otherwise the use by the Licensee would be an infringement of the owner’s rights and could be prevented.

Subject to laws relating to competition and export control, it is principally up the parties to agree on the rights to be the subject of the licence and the extent, duration and purpose of the use to be made of such rights by the Licensee. As such licences are extremely flexible, the forms of enabling the exploitation of intellectual property rights need careful consideration to ensure that they are effective and do not impinge on the Licensor’s freedom to exploit the rights in areas which it wants to exploit itself.

The terms will also depend on the role that the Licensor wishes to take in the exploitation (e.g. to make and sell products or parts of them) or to design the technology and license it, the rights being licensed, the technologies, products or processes to which they relate and the markets into which they will be sold recognising that these will inevitably change over time.

Examples of the types of considerations that need to be thought about when granting a licence include the following: -

  • ‍Purpose of the licence‍

Is the licence an enabling part of a wider purpose such as a joint development or collaboration or is it to enable an interested licensee access to a product or process to enable them to develop it in their market? ‍

  • Geographical extent‍

The licence could be worldwide, limited to economic areas like the North America or the EU or more specific territories such as individual countries or even regions of countries.‍

  • Duration‍

How long will the license last, is it for the life of the last of the patents being licensed to expire, subject to rights of earlier termination for breach, other forms of non- performance and insolvency ?‍

  • Field of Use‍

Platform technologies or technologies which can be used in several different areas of economic activity can be licensed for specific uses – such as that described in the Maxion Master Development Agreement. This enables the Licensor to exploit the technology to the full by appointing licensees best able to exploit that field. ‍

  • Rights to exploit‍

What rights will the Licensee have? Will they be able to develop the technology itself (and what happens to the rights they create as a result), manufacture, sell, and support in the after sales market or will they, for example, be restricted to just making and not selling other than to the Licensor and its distributors? Will manufacturing rights be restricted to a particular geographic area?‍

  • Obligations to maintain and enforce the licensed rights‍

Who will be primarily responsible for keeping the rights in force (and importantly paying the not insignificant costs of so doing) and taking action against infringers? What happens if one party wants to stop paying patent prosecution or renewal costs and the other party disagrees?‍

  • Exclusivity‍

Will the licence be exclusive, sole or non-exclusive to the Licensee (sole typically means that the rights are restricted to the Licensor and the Licensor)?‍

  • Rights to assign and sub-licence‍

Can the Licensee assign its rights and if so to whom? Can the Licensee sub-license the rights and for what purposes?‍

  • Royalties and lump sum payments:

How will the Licensee pay for the rights it has been granted? Typically, this is by way of a percentage payment on the final selling price (usually excluding tax and often costs like insurance, freight costs and returns) of the products or processes the subject of the licence. However, these can be structured as minimum royalties (assuming minimum sales) or advance royalties (paid in advance of the sales expected to be made) as well as running royalties on products actually sold. In addition, particularly for products in development when licensed it is common for a Licensee to pay a lump sum payment to the Licensor when either party achieves a milestone such as obtaining a regulatory clearance. ‍

  • Improvements

This is touched on above but is a key consideration for products in development or which can be improved and further developed (e.g. software). Who will own the improvement and what value is to be applied to them? Who will be able to use them for commercial exploitation and in what area? Does it matter if the improvement can only be used in conjunction with the rights being licensed?‍

  • Allocation of risk‍

There are always risks incumbent on parties undertaking a commercial relationship and these need to be allocated and in certain cases limited or excluded. For example, it is common for a Licensor to indemnify the Licensee against the risk that third party rights might be infringed and for the Licensee to indemnify the Licensor against product liability risks caused by defects in the Licensee’s implementation of the technology.‍

  • Termination‍

What rights should either party have to terminate the licence and what are the consequences of termination – for example, it is not uncommon for a licensee to retain rights to continue to exploit the technology notwithstanding termination of the licence in some circumstances particularly where the licensee has invested heavily in its success

  • Governing Law and Jurisdiction

This is often a tricky area for smaller companies granting licences to bigger ones. The bigger company demands its own jurisdiction although it is better able to manage litigation in different territories because it seeks to discourage the smaller party from undertaking the expense and management time needed to mange litigation in a different territory and one that it is unfamiliar with. In addition, if the Licensor is granting a number of similar licences it will want to be very careful about having them subject to different laws and jurisdictions since that will complicate their meaning as well as their management.

3. Joint Venture Structures

Licensing strategies often take the form of a key part of a wider commercial relationship between companies particularly in developing technologies where collaborative agreements allow the parties to bring their respective. skills and knowledge to achieve a common goal. There are a number of legal structures which can be adopted to achieve this end. Joint venture arrangements include the following:

  • Corporate joint venture

Where the parties set up a special purpose vehicle (“SPV”) to own and control a business venture in which the shares are owned by the participants, and which can be used to bring in further participants by way of investment or additional technology.

  • Contractual joint ventures

Where there is no SPV but a contractual arrangement governing each parties’ rights and obligations under the business venture including how the collaboration should work and what intellectual property rights are licensed to each party and what rights they have in respect of them and any improvements made as a result of the collaboration.

  • Specialisation Agreements

Where each party agrees to focus on an aspect of the development so that one party will focus on, e.g. the manufacture and/or sale of a particular product while the other might focus on developing improvements and the manufacture of a different component.

Such arrangements are invariably complex to negotiate and document and require experienced counsel to deliver them in a form likely to survive the trials and tribulations of such relationships.

4. Intellectual property rights management

It is also wise to give early thought as to how the ownership and management (including licensing) of intellectual property rights should be handled.

The use of an IP holding company (which is not trading or, if it is, doing so only in so far as necessary for the purposes of the management, licensing and enforcement of IP) is a useful way to separate the ownership of a key business asset from the financial and other risks faced by operating entities in the business which can result from the appointment of administrators, receivers and liquidators.

This can protect the IP from those risks and liabilities. It is important in so doing to emphasise the independence of the IP holding company from the rest of the group by, in time, giving it its own management, board and governance. Further, dealings with the remainder of the group should be conducted on an arm’s length basis so far as it practical to do so. These steps are ultimately important for any tax structuring, but it is also important to avoid claims of acting in concert or being joint actors in any situations which give rise to existential risk.

Depending on the development stage of the business it may also be feasible for the IP holding company to have employees whose duties exclusively relate to the management, licensing and enforcement of the IP such as patent counsel and paralegals and (importantly for tax structuring) those involved in research and development. It is better if such employees are not directly involved in the group’s day-to-day commercial activities, as this will assist in ring-fencing the IP. There can of course be overlap at director level and the shareholdings will mean that the company is ultimately under the control of a holding company in the group, but as much separation as is practical is useful.

The intra-group assignment and licensing of IP necessary to achieve such ring fencing should be properly documented (including by recording assignments and licences in national IP offices where it is legally advisable to do so – such as the UK) and accounted in the corporate books and records. For a greater level of protection, the IP holding company may set up a subsidiary or subsidiaries dedicated to licensing third parties, further separating the IP holding company from trading and financial risk. Intra- group licensing needs to take account of national laws which may impact on how IP rights can be enforced by assignees and licensees. For example, in the UK, non- exclusive licensees do not have the automatic right to take action for infringement of trademarks, copyrights or patents in their own name and, if transactions are not recorded in at the UKIPO within 6 months of the date of the transaction, rights against third party interlopers and infringers may be lost or limited.

Conclusion

In summary, a robust commercial licensing strategy is essential for unlocking the full value of intellectual property, whether through understanding IP as a property right, structuring effective licences, forming joint ventures, or managing rights efficiently. By taking a proactive and informed approach, businesses can maximise opportunities and minimise risks in today’s dynamic market.

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​